低危患者经导管与外科主动脉瓣置换术比较
该荟萃分析纳入4项随机对照试验共2887例低危(STS-PROM<4%)重度主动脉瓣狭窄患者,比较TAVR与SAVR。结果显示TAVR组1年全因死亡和心血管死亡风险显著低于SAVR,但永久起搏器植入和中重度瓣周漏发生率更高。
要点
- 低危重度AS患者TAVR较SAVR降低1年全因死亡风险(RR 0.61)。
- TAVR组永久起搏器植入和中重度瓣周漏发生率高于SAVR。
- TAVR可作为低危重度AS患者生物瓣置换的优先选择。
核心结论
- 在低危重度AS患者中,TAVR较SAVR显著降低1年全因死亡和心血管死亡风险。
研究设计与样本
- 随机对照试验的荟萃分析,纳入4项RCT共2887例低危患者(TAVR 1497例,SAVR 1390例),平均年龄75.4岁,平均STS-PROM 2.3%。
主要发现
- TAVR组1年全因死亡2.1% vs SAVR 3.5%(RR 0.61,95%CI 0.39-0.96,p=0.03,I2=0%)。
- TAVR组1年心血管死亡1.6% vs SAVR 2.9%(RR 0.55,95%CI 0.33-0.90,p=0.02,I2=0%)。
- TAVR组新发/加重房颤、危及生命/致残性出血、急性肾损伤2/3期发生率更低。
- TAVR组永久起搏器植入和中重度瓣周漏发生率更高。
- 两组在大血管并发症、心内膜炎、主动脉瓣再干预及NYHA≥II级方面无显著差异。
关键数值与推荐
- 低危定义为STS-PROM评分<4%。
- 主要终点为1年全因死亡。
临床怎么用
- 对于低危重度AS且适合生物瓣置换的患者,TAVR可作为优先于SAVR的选择。
- 需权衡TAVR较高的起搏器植入和瓣周漏风险与较低的死亡和出血风险。
局限性
- 检索截止2019年3月20日,未纳入此后发表的研究。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transcatheter aortic valve replacement (TAVR) has emerged as a safe and effective therapeutic option for patients with severe aortic stenosis (AS) who are at prohibitive, high, or intermediate risk for surgical aortic valve replacement (SAVR). However, in low-risk patients, SAVR remains the standard therapy in current clinical practice. OBJECTIVES: This study sought to perform a meta-analysis of randomized controlled trials (RCTs) comparing TAVR versus SAVR in low-risk patients. METHODS: Electronic databases were searched from inception to March 20, 2019. RCTs comparing TAVR versus SAVR in low-risk patients (Society of Thoracic Surgeons Predicted Risk of Mortality [STS-PROM] score <4%) were included. Primary outcome was all-cause death at 1 year. Random-effects models were used to calculate pooled risk ratio (RR) and corresponding 95% confidence interval (CI). RESULTS: The meta-analysis included 4 RCTs that randomized 2,887 patients (1,497 to TAVR and 1,390 to SAVR). The mean age of patients was 75.4 years, and the mean STS-PROM score was 2.3%. Compared with SAVR, TAVR was associated with significantly lower risk of all-cause death (2.1% vs. 3.5%; RR: 0.61; 95% CI: 0.39 to 0.96; p = 0.03; I2 = 0%) and cardiovascular death (1.6% vs. 2.9%; RR: 0.55; 95% CI: 0.33 to 0.90; p = 0.02; I2 = 0%) at 1 year. Rates of new/worsening atrial fibrillation, life-threatening/disabling bleeding, and acute kidney injury stage 2/3 were lower, whereas those of permanent pacemaker implantation and moderate/severe paravalvular leak were higher after TAVR versus SAVR. There were no significant differences between TAVR versus SAVR for major vascular complications, endocarditis, aortic valve re-intervention, and New York Heart Association functional class ≥II. CONCLUSIONS: In this meta-analysis of RCTs comparing TAVR versus SAVR in low-risk patients, TAVR was associated with significantly lower risk of all-cause death and cardiovascular death at 1 year. These findings suggest that TAVR may be the preferred option over SAVR in low-risk patients with severe AS who are candidates for bioprosthetic AVR.
引用
- Kolte D, Vlahakes GJ, Palacios IF, et al. Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients. J Am Coll Cardiol. 2019. PMID: 31537261. doi:10.1016/j.jacc.2019.06.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。